Ergomed Aktie kaufenswert? (Seite 5)
eröffnet am 01.12.16 16:57:13 von
neuester Beitrag 04.09.23 10:24:12 von
neuester Beitrag 04.09.23 10:24:12 von
Beiträge: 415
ID: 1.242.462
ID: 1.242.462
Aufrufe heute: 0
Gesamt: 19.692
Gesamt: 19.692
Aktive User: 0
ISIN: GB00BN7ZCY67 · WKN: A117XM
15,480
EUR
+0,06 %
+0,010 EUR
Letzter Kurs 08.11.23 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 1,1500 | +34,98 | |
| 1,0000 | +33,33 | |
| 6,5900 | +31,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 35,69 | -13,71 | |
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 | |
| 1,2700 | -19,62 | |
| 2.849,50 | -83,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Annual General Meeting Statement
Guildford, UK - 10 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the following update from Dr Miroslav Reljanović, Executive Chairman, in advance of the Company's closed Annual General Meeting ('AGM') to be held this morning at 9.30am :
"Ergomed has had a strong start to 2021. In the year to date, the conclusion of our strategic transition to a services-based business model, coupled with our ongoing resilience globally through the COVID-19 pandemic, has enabled the Company to build further on the momentum seen in 2020.
"The Company has continued to make significant strategic progress in the current year. With the integration of the Ashfield Pharmacovigilance business successfully concluded, PrimeVigilance, the Company's pharmacovigilance division, has seen continued strong growth in revenues in line with prior trends. In the CRO business, integration of MedSource, which was acquired in December 2020, is progressing well and our CRO business as a whole is seeing further acceleration in the growth that resumed in the second half of 2020.
"Alongside strong organic growth, the integration of the two new businesses is continuing to fuel rapid development of the Company's operational presence in the US. At the same time, the Company's international growth is continuing, with ongoing expansion into further geographic areas, including the recently announced new operation in Japan , the fourth largest pharmaceutical market in the world .
" With continuing strong sales and order book growth, solid trading in the first months of the year, effective cost management and acquisition synergies, the Board currently expects adjusted EBITDA for the full year to be materially ahead of market expectations. Reported revenues for the full year are expected to be in line with market expectations, notwithstanding a higher proportion of US dollar denominated revenues leading to some FX headwinds.
"In accordance with our usual practice, in July 2021 we will provide a more detailed report on current trading and a further update on the outlook for the 2021 financial year as a whole.
"Finally, on behalf of the Board, I would like to thank all of the Company's colleagues and shareholders for their continuing support through the challenging times of the past year, as we look forward with optimism to the rest of the year."
Guildford, UK - 10 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the following update from Dr Miroslav Reljanović, Executive Chairman, in advance of the Company's closed Annual General Meeting ('AGM') to be held this morning at 9.30am :
"Ergomed has had a strong start to 2021. In the year to date, the conclusion of our strategic transition to a services-based business model, coupled with our ongoing resilience globally through the COVID-19 pandemic, has enabled the Company to build further on the momentum seen in 2020.
"The Company has continued to make significant strategic progress in the current year. With the integration of the Ashfield Pharmacovigilance business successfully concluded, PrimeVigilance, the Company's pharmacovigilance division, has seen continued strong growth in revenues in line with prior trends. In the CRO business, integration of MedSource, which was acquired in December 2020, is progressing well and our CRO business as a whole is seeing further acceleration in the growth that resumed in the second half of 2020.
"Alongside strong organic growth, the integration of the two new businesses is continuing to fuel rapid development of the Company's operational presence in the US. At the same time, the Company's international growth is continuing, with ongoing expansion into further geographic areas, including the recently announced new operation in Japan , the fourth largest pharmaceutical market in the world .
" With continuing strong sales and order book growth, solid trading in the first months of the year, effective cost management and acquisition synergies, the Board currently expects adjusted EBITDA for the full year to be materially ahead of market expectations. Reported revenues for the full year are expected to be in line with market expectations, notwithstanding a higher proportion of US dollar denominated revenues leading to some FX headwinds.
"In accordance with our usual practice, in July 2021 we will provide a more detailed report on current trading and a further update on the outlook for the 2021 financial year as a whole.
"Finally, on behalf of the Board, I would like to thank all of the Company's colleagues and shareholders for their continuing support through the challenging times of the past year, as we look forward with optimism to the rest of the year."
M&A remains on the agenda with plenty of firepower
Ergomed has repeated on several occasions that it aims to expand via both organic top-line growth and M&A.
EdisonGroup: Ergomed Valuation: £683m or 1,400p/share
https://www.edisongroup.com/publication/whats-next-after-ste…
Ergomed has repeated on several occasions that it aims to expand via both organic top-line growth and M&A.
EdisonGroup: Ergomed Valuation: £683m or 1,400p/share
https://www.edisongroup.com/publication/whats-next-after-ste…
Morgen ist Ergomed bei "Jefferie" - gespannt was es zu verkünden gibt. Auf alle Fälle läuft es.
Ergomed to Present at Jefferies Conference
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed…
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed…
Notice of AGM and Annual Report
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/notice-…
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/notice-…
Trading Spotlight
NEWS: European Mediscience Awards 2021. Ergomed has been shortlisted for “Best Communication Award” and “Company of the Year”.
http://www.mediscience-event.co.uk/nominations-overview/
http://www.mediscience-event.co.uk/nominations-overview/
Mark Enyedy Appointed to Board as Non-Executive Director
Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.
Prior to ImmunoGen, Mr Enyedy served in various executive capacities at Shire plc, including as Executive Vice President and Head of Corporate Development, a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at Genzyme Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/board-c…
Mr Enyedy brings more than 25 years of senior leadership experience in the biopharmaceutical sector, including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He is currently President and Chief Executive Officer and a Director of ImmunoGen, Inc., a publicly-traded biotechnology company, where he oversees strategy and operations. He is also a member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.
Prior to ImmunoGen, Mr Enyedy served in various executive capacities at Shire plc, including as Executive Vice President and Head of Corporate Development, a role in which he negotiated and integrated the multi-billion dollar acquisitions of NPS Pharmaceuticals and Dyax Corp. and oversaw the $32 billion combination with Baxalta, Inc. Mr Enyedy was also previously President of the Transplant, Oncology and Multiple Sclerosis division at Genzyme Corporation, and under his leadership the division achieved revenue growth from under $10 million to more than $675 million in just seven years. He began his career as an attorney at Palmer & Dodge, a Boston-based law firm where his practice focused on representing biopharmaceutical, high technology, and energy companies in M&A, licensing, and financing transactions.
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/board-c…
UK's Ergomed expands pharmacovigilance business operations in Japan
https://www.biospectrumasia.com/news/90/18063/uks-ergomed-ex…
https://www.biospectrumasia.com/news/90/18063/uks-ergomed-ex…
... die 20 Euro sind im Blick.
Durchsuchen
